Navigation Links
Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
Date:3/10/2009

'Trial Meets Primary and Key Secondary Endpoints'

NEW YORK, March 10 /PRNewswire/ -- Intra-Cellular Therapies, Inc. today announced the final results from the ITI-007 Phase II trial in patients with Sleep Maintenance Insomnia (SMI). In this study, ITI-007 significantly and dose-dependently increased slow wave sleep and decreased the duration of wake after sleep onset as measured by polysomnography (PSG), meeting the prespecified primary and key secondary endpoints of the trial. ITI-007 also increased total sleep time and sleep efficiency. PSG improvements such as increased total sleep time and slow wave sleep are associated with reports of improved sleep quality. Improvement in these sleep parameters is driven by the unique pharmacology of ITI-007 that can act simultaneously as a 5HT2A receptor antagonist, dopamine receptor phosphoprotein modulator (DPPM), and inhibitor of serotonin reuptake. These additional actions clearly differentiate ITI-007 from other sleep modulating drugs. The present Phase II data suggest the beneficial effects on sleep are a result of ITI-007's distinctive neuropharmacological mechanisms beyond simple 5HT2A receptor antagonism. As such, ITI-007 represents a novel approach for the treatment of insomnia characterized by difficulty in staying asleep, as well as for the treatment of insomnia related to psychiatric and neurologic disorders. These clinical results will be presented at a major scientific meeting in June.

"We are excited to have demonstrated ITI-007's ability to produce such robust improvements on sleep quality," stated Sharon Mates, Chief Executive Officer of Intra-Cellular Therapies. "We believe that the positive effects on sleep in this study are a result of ITI-007's unique pharmacological profile that clearly differentiate it from currently available sleep inducing or sleep maintaining drugs. These data set the stage for further investigation of ITI-007's ability to improve slee
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
3. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
4. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
5. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
6. Old and new therapies combine to tackle atherosclerosis
7. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
8. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
9. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
10. Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Carolina State University have developed a technique for controlling ... low voltages, opening the door to a new generation ... technique hinges on the fact that the oxide "skin" ... removed acts as a surfactant, lowering the surface ... The researchers used a liquid metal alloy of gallium ...
(Date:9/15/2014)... 15, 2014 Zymo Research Corp., has announced ... for safe ambient temperature storage and transport of ... infectivity of agents in such samples is completely ... of the viral nucleic acids for subsequent analyses.  ... epidemic in West Africa ...
(Date:9/15/2014)... 15. September 2014 Die zweite jährliche ... vom 12. bis 18. Oktober stattfinden. Die IPAW ... Therapeutics Association (PPTA) und ihrer Mitgliedsunternehmen ... Das globale Bewusstsein für die Gewinnung von Quellplasma ... beim Retten und Verbessern von Leben zu würdigen ...
(Date:9/14/2014)... MD (PRWEB) September 15, 2014 ... be held on Tuesday, October 21, 2014, from 12:00 ... overview of the program’s innovative curriculum and practice-oriented instruction, ... a graduate degree can help advance their career in ... RSVP online . , About UMBC’s Biotechnology ...
Breaking Biology Technology:Researchers control surface tension to manipulate liquid metals 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2
... (Nasdaq: VNDA ), a biopharmaceutical company focused ... for central,nervous system disorders, today announced financial and ... 2008., Vanda reported research and development (R&D) ... million, compared to $5.5 million in the second,quarter ...
... STERIS Corporation,(NYSE: STE ) today announced financial ... 2008. Fiscal 2009 second quarter revenues,increased 10% to $323.1 ... fiscal 2008, driven by strong growth in all three ... million, or $0.48,per diluted share, compared with net income ...
... Genetic Variations Identify Predisposition to Early Cardiovascular,Events in ... Interleukin Genetics,Inc. (Amex: ILI ), announced today ... will present new research findings on,the genetics of ... Symposium (CVGAS), which takes place from Oct. 31 ...
Cached Biology Technology:Vanda Pharmaceuticals Reports Third Quarter 2008 Results 2Vanda Pharmaceuticals Reports Third Quarter 2008 Results 3Vanda Pharmaceuticals Reports Third Quarter 2008 Results 4Vanda Pharmaceuticals Reports Third Quarter 2008 Results 5Vanda Pharmaceuticals Reports Third Quarter 2008 Results 6Vanda Pharmaceuticals Reports Third Quarter 2008 Results 7Vanda Pharmaceuticals Reports Third Quarter 2008 Results 8Vanda Pharmaceuticals Reports Third Quarter 2008 Results 9Vanda Pharmaceuticals Reports Third Quarter 2008 Results 10STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 2STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 3STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 4STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 5STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 6STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 7STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 8STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 9STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 10STERIS Corporation Announces Fiscal 2009 Second Quarter and First Half Results 11Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium 2Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium 3Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium 4
(Date:9/15/2014)... for both plants and animals alike. , Understanding just ... lead to the design of better drugs for diabetes ... and vegetables farmers are able to grow. Stanford University ... the cell by piecing together proteins slightly wider than ... To determine the size, shape and orientation of one ...
(Date:9/15/2014)... ecologists fears that reef biodiversity may not provide the ... thought. , In an international study published today, Professor ... Coral Reef Studies (Coral CoE) says we need to ... ecosystems. , In coral reefs, just as in any ... ecosystem safe and functioning. , Professor Bellwood says, ...
(Date:9/15/2014)... the first 500 million years after it formed may ... with oceans, continents and active crustal plates. , This ... Hadean, has gained substantial new support from the first ... 4 billion years ago with those formed contemporaneously in ... analog for early Earth. , The study was conducted ...
Breaking Biology News(10 mins):X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3Specialized species critical for reefs 2Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... chief executive officer of DuPont, and Abby Joseph Cohen, ... & Co., will be featured speakers at a University ... to be held Friday, Nov. 2, in Clayton Hall, ... conference is the first in a new series of ...
... of marine microbes have been discovered at two deep-sea ... the MBL (Marine Biological Laboratory) and University of Washingtons ... Their findings, published in the October 5 issue of ... comprehensive, comparative study to date of deep-sea microbial communities ...
... (ESA) is proud to announce its selection of ... as an ESA Fellow acknowledges outstanding contributions in research, ... have have participated actively in ESA affairs and served ... be recognized during the ESA Annual Meeting, which will ...
Cached Biology News:UD hosts conference on knowledge-based partnerships Nov. 2 2Hydrothermal vents: Hot spots of microbial diversity 2Entomological Society of America recognizes 2007 fellows and honorary members 2Entomological Society of America recognizes 2007 fellows and honorary members 3
Applications: Western blotting ...
...
... efficiencies and the chemistry of light production ... benefit that they require simple triggering conditions ... This benefit has been exploited to great ... compounds can also be easily modified to ...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
Biology Products: